Bernstein SocGen Group Upgrades Edwards Lifesciences (EW) to Market Perform

Goldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)

Goldman Sachs analyst David Roman reiterated a Buy rating and $80.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst comments "Overall, we think confirmatory results for the full cohort of TRISCEND II was broadly expected by investors we have spoken... More

BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)

BofA Securities analyst Travis Steed reiterated a Neutral rating and $75.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst comments "On Wednesday EW hosted a TMTT investor event after Evoque pivotal data were presented. See TRISCEND II at TCT report for our initial take on the data. We go over the key... More

Edwards Lifesciences (EW) PT Raised to $85 at Barclays

Barclays analyst Matt Miksic raised the price target on Edwards Lifesciences (NYSE: EW) to $85.00 (from $80.00) while maintaining a Overweight rating.... More

Edwards Lifesciences (EW) PT Lowered to $70 at Piper Sandler

Piper Sandler analyst Adam Maeder lowered the price target on Edwards Lifesciences (NYSE: EW) to $70.00 (from $73.00) while maintaining a Neutral rating.

The analyst commented, "Tonight, EW announced Q3 results with both TAVR and TMTT coming in slightly ahead of Street expectations. EW reported Q3... More

Edwards Lifesciences (EW) PT Lowered to $63 at Canaccord Genuity

(Updated - October 25, 2024 7:53 AM EDT)

Canaccord Genuity analyst William Plovanic lowered the price target on Edwards Lifesciences (NYSE: EW) to $63.00 (from $66.00) while maintaining a Hold rating.

The analyst commented: "With lots of moving parts, wed call EWs Q3 results relatively in line with our expectations. The company reported Q3 net sales of $1,354.4M (+9% Y/Y adjusted, +10% Y/Y CC), which compared to our $1,370.2M estimate and consensus of $1,356M. Our estimate did not fully eliminate some of the... More

TD Cowen Reiterates Hold Rating on Edwards Lifesciences (EW)

TD Cowen analyst Joshua Jennings reiterated a Hold rating and $70.00 price target on Edwards Lifesciences (NYSE: EW).

The analyst commented, "After the dramatic reset in growth expectations and EW's share price that accompanied the 2Q print, its 3Q results were far less... More

Edwards Lifesciences (EW) PT Raised to $78 at JPMorgan

JPMorgan analyst Robbie Marcus raised the price target on Edwards Lifesciences (NYSE: EW) to $78.00 (from $72.00) while maintaining a Neutral rating.... More

Edwards Lifesciences (EW) PT Lowered to $68 at Baird

Baird analyst David Rescott lowered the price target on Edwards Lifesciences (NYSE: EW) to $68.00 (from $73.00) while maintaining a Neutral rating.... More

Edwards Lifesciences (EW) PT Lowered to $70 at Truist Securities

Truist Securities analyst Richard Newitter lowered the price target on Edwards Lifesciences (NYSE: EW) to $70.00 (from $71.00) while maintaining a Hold rating.

The analyst comments "Discont'd operations made for a messy 3Q, but WW TAVR & TMTT delivered slight upside. Still, uncertainty remains around TAVR growth... More

BTIG Reiterates Neutral Rating on Edwards Lifesciences (EW)

BTIG analyst Marie Thibault reiterated a Neutral rating on Edwards Lifesciences (NYSE: EW).

The analyst comments "There were a few moving parts with this quarter's print following the sale of the Critical Care business in September as well as the discontinuation of a small non-core product group in the Surgical Structural Heart business that generates ~$60-70M in annual sales. Excluding these items, EW grew revenue by 9.6% y/y CC in Q3 and reported adj. EPS of $0.67. Total TAVR sales of $1.023B were $13M above consensus of $1.010B (+6.5% y/y rep., +7.2% CC).... More

After-hours movers: Capri Holdings, Skechers, DexCom, Western Digital and more

After-Hours Stock Movers:

Capri Holdings (NYSE: CPRI) shares fell 48% after a judge blocked its deal to merge with Tapestry (NYSE: TPR), a victory for the FTC. Tapestry shares gained.

DexCom (NASDAQ:... More

Edwards Lifesciences (EW) Tops Q3 EPS by 1c; offers guidance

Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.67, $0.01 better than the analyst estimate of $0.66. Revenue for the quarter came in at $1.35 billion versus the consensus estimate of $1.57 billion.

GUIDANCE:

Edwards Lifesciences sees Q4 2024 EPS of $0.53-$0.57, versus the consensus of $0.60.... More